Abstract
Lead exposure increases blood pressure (BP) by unknown mechanisms. Many recent studies have shown the involvement of matrix metalloproteinases (MMPs) in hypertension, particularly MMP-2. In this work, we have examined whether MMP-2 levels increase with lead-induced increase in BP. We have also investigated whether doxycycline (an MMP inhibitor) affects these alterations. To this end, rats were exposed to lead (90 ppm) and treated with doxycycline or vehicle for 8 weeks. Similar aortic and whole blood lead levels were found in lead-exposed rats treated with either doxycycline or vehicle. Lead-induced increases in BP and aortic MMP-2 levels (activity, protein, and mRNA) were blunted by doxycycline. Doxycycline also prevented lead-induced increases in the MMP-2/TIMP-2 mRNA ratio. No significant changes in vascular reactivity or morphometric parameters were found. In conclusion, lead exposure increases BP and vascular MMP-2, which is blunted by doxycycline. This observation suggests that MMP-2 may play a role in lead-induced increases in BP.
Similar content being viewed by others
References
Altieri P, Brunelli C, Garibaldi S, Nicolino A, Ubaldi S, Spallarossa P, Olivotti L, Rossettin P, Barsotti A, Ghigliotti G (2003) Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure. Eur J Clin Invest 33:648–656
Barbosa F Jr, Gerlach RF, Tanus-Santos JE (2006) Matrix metalloproteinase-9 activity in plasma correlates with plasma and whole blood lead concentrations. Basic Clin Pharmacol Toxicol 98:559–564
Bernard A, Lauwerys R (1987) Metal-induced alterations of delta-aminolevulinic acid dehydratase. Ann N Y Acad Sci 514:41–47
Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107:1579–1585
Bouvet C, Gilbert LA, Girardot D, deBlois D, Moreau P (2005) Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 45:432–437
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
Carmignani M, Boscolo P, Poma A, Volpe AR (1999) Kininergic system and arterial hypertension following chronic exposure to inorganic lead. Immunopharmacology 44:105–110
Carmignani M, Volpe AR, Boscolo P, Qiao N, Di Gioacchino M, Grilli A, Felaco M (2000) Catcholamine and nitric oxide systems as targets of chronic lead exposure in inducing selective functional impairment. Life Sci 68:401–415
Castro MM, Rizzi E, Rascado RR, Nagassaki S, Bendhack LM, Tanus-Santos JE (2004) Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur J Pharmacol 498:189–194
Castro MM, Rizzi E, Figueiredo-Lopes L, Fernandes K, Bendhack LM, Pitol DL, Gerlach RF, Tanus-Santos JE (2008) Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198:320–321
Courtois E, Marques M, Barrientos A, Casado S, Lopez-Farre A (2003) Lead-induced downregulation of soluble guanylate cyclase in isolated rat aortic segments mediated by reactive oxygen species and cyclooxygenase-2. J Am Soc Nephrol 14:1464–1470
Dao HH, Lemay J, de Champlain J, deBlois D, Moreau P (2001) Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent. J Hypertens 19:1965–1973
Ding Y, Gonick HC, Vaziri ND (2000) Lead promotes hydroxyl radical generation and lipid peroxidation in cultured aortic endothelial cells. Am J Hypertens 13:552–555
Ding Y, Gonick HC, Vaziri ND, Liang K, Wei L (2001) Lead-induced hypertension. III. Increased hydroxyl radical production. Am J Hypertens 14:169–173
Escolar JD, Tejero C, Escolar MA, Montalvo F, Garisa R (1997a) Architecture, elastic fiber, and collagen in the distal air portion of the lung of the 18-month-old rat. Anat Rec 248:63–69
Escolar JD, Tejero C, Escolar MA, Montalvo F, Garisa R (1997b) Methodological contributions for the morphometric study of the lung: approximation to the ideal sample size and quantification of collagen fiber. Anat Rec 247:501–511
Fernandez-Patron C, Radomski MW, Davidge ST (1999) Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85:906–911
Fernandez-Patron C, Stewart KG, Zhang Y, Koivunen E, Radomski MW, Davidge ST (2000) Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ Res 87:670–676
Gerlach RF, de Souza AP, Cury JA, Line SR (2000) Effect of lead, cadmium and zinc on the activity of enamel matrix proteinases in vitro. Eur J Oral Sci 108:327–334
Hao L, Du M, Lopez-Campistrous A, Fernandez-Patron C (2004) Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 94(1):68–76. Epub 2003 Dec 1
Jurczuk M, Moniuszko-Jakoniuk J, Brzoska MM (2006) Involvement of some low-molecular thiols in the peroxidative mechanisms of lead and ethanol action on rat liver and kidney. Toxicology 219:11–21. Epub 2005 Dec 2002
Karimi G, Khoshbaten A, Abdollahi M, Sharifzadeh M, Namiranian K, Dehpour AR (2002) Effects of subacute lead acetate administration on nitric oxide and cyclooxygenase pathways in rat isolated aortic ring. Pharmacol Res 46:31–37
Kasperczyk S, Dziwisz M, Kasperczyk A, Birkner E (2002) Influence of lead exposure on arterial hypertension. Wiad Lek 55(Suppl 1):230–234
Khalil-Manesh F, Gonick HC, Weiler EW, Prins B, Weber MA, Purdy RE (1993) Lead-induced hypertension: possible role of endothelial factors. Am J Hypertens 6:723–729
Lahat N Fau, Shapiro S, Froom P, Kristal-Boneh E, Inspector M, Miller A (2002) Inorganic lead enhances cytokine-induced elevation of matrix metalloproteinase MMP-9 expression in glial cells. J Neuroimmunol 132(1–2):123–128
Lehoux S, Lemarie CA, Esposito B, Lijnen HR, Tedgui A (2004) Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation 109:1041–1047
Lima EC, Barbosa F Jr, Krug FJ (2001) Lead determination in slurries of biological materials by ETAAS using a W-Rh permanent modifier. Fresenius J Anal Chem 369:496–501
Lynch JR, Blessing R, White WD, Grocott HP, Newman MF, Laskowitz DT (2004) Novel diagnostic test for acute stroke. Stroke 35:57–63
Marques M, Millas I, Jimenez A, Garcia-Colis E, Rodriguez-Feo JA, Velasco S, Barrientos A, Casado S, Lopez-Farre A (2001) Alteration of the soluble guanylate cyclase system in the vascular wall of lead-induced hypertension in rats. J Am Soc Nephrol 12:2594–2600
Martin D, Glass TA, Bandeen-Roche K, Todd AC, Shi W, Schwartz BS (2006) Association of blood lead and tibia lead with blood pressure and hypertension in a community sample of older adults. Am J Epidemiol 163:467–478
Martinez A, Oh HR, Unsworth EJ, Bregonzio C, Saavedra JM, Stetler-Stevenson WG, Cuttitta F (2004) Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 383:413–418
Nelson KK, Melendez JA (2004) Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 37:768–784
Neuberger JS, Mulhall M, Pomatto MC, Sheverbush J, Hassanein RS (1990) Health problems in Galena, Kansas: a heavy metal mining Superfund site. Sci Total Environ 94:261–272
Purdy RE, Smith JR, Ding Y, Oveisi F, Vaziri ND, Gonick HC (1997) Lead-induced hypertension is not associated with altered vascular reactivity in vitro. Am J Hypertens 10:997–1003
Ra HJ, Parks WC (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol 26:587–596
Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA (2001) Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem 8:305–316
Sang QX, Stetler-Stevenson WG, Liotta LA, Byers SW (1990) Identification of type IV collagenase in rat testicular cell culture: influence of peritubular-Sertoli cell interactions. Biol Reprod 43(6):956–964
Schulz R (2007) Intracellular targets of matrix metalloproteinase-2 in cardiac disease: rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 47:211–242
Shelkovnikov SA, Gonick HC (2001) Influence of lead on rat thoracic aorta contraction and relaxation. Am J Hypertens 14:873–878
Skoczynska A, Wrobel J, Andrzejak R (2001) Lead-cadmium interaction effect on the responsiveness of rat mesenteric vessels to norepinephrine and angiotensin II. Toxicology 162:157–170
Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE (2005) Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 38:410–414
Stricklin GP, Jeffrey JJ, Roswit WT, Eisen AZ (1983) Human skin fibroblast procollagenase: mechanisms of activation by organomercurials and trypsin. Biochemistry 22:61–68
Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY (2004) Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 17:764–769
Tsao DA, Yu HS, Cheng JT, Ho CK, Chang HR (2000) The change of beta-adrenergic system in lead-induced hypertension. Toxicol Appl Pharmacol 164:127–133
Van Wart HE, Birkedal-Hansen H (1990) The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 87:5578–5582
Vaziri ND, Ding Y (2001) Effect of lead on nitric oxide synthase expression in coronary endothelial cells: role of superoxide. Hypertension 37:223–226
Vaziri ND, Ding Y, Ni Z, Gonick HC (1997) Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int 52:1042–1046
Vaziri ND, Ding Y, Ni Z (2001) Compensatory up-regulation of nitric-oxide synthase isoforms in lead-induced hypertension; reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther 298:679–685
Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827–839
Walter A, Etienne-Selloum N, Sarr M, Kane MO, Beretz A, Schini-Kerth VB (2008) Angiotensin II induces the vascular expression of VEGF and MMP-2 in vivo: preventive effect of red wine polyphenols. J Vasc Res 45:386–394
Watts SW, Rondelli C, Thakali K, Li X, Uhal B, Pervaiz MH, Watson RE, Fink GD (2007) Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol 292:H2438–H2448
Webb RC, Winquist RJ, Victery W, Vander AJ (1981) In vivo and in vitro effects of lead on vascular reactivity in rats. Am J Physiol 241:H211–H216
Winneke G (1986) Animal studies. In: Lead toxicity, history and environmental impact. Landsdown R, Yule W (eds) The Johns Hopkins University Press, Baltimore, pp 217–233
Woessner JF Jr (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145–2154
Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, Ashby MJ, Cockcroft JR, Wilkinson IB (2005) Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25:372
Zhou Y, Zanao RA, Barbosa F, Parsons PJ, Krug FJ (2002) Investigations on a W-Rh permanent modifier for the detection of Pb in blood by electrothermal atomic absorption spectrometry. Spectrochim Acta Part B 57:1291–1300
Acknowledgments
This study was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP-Brazil; FAPESP-Cinapce-Brazil), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq-Brazil), and PROEX-CAPES (Brazil). We gratefully acknowledge the excellent technical support of Dimitrius Leonardo Pitol.
Conflict of Interest statement
None declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rizzi, E., Castro, M.M., Fernandes, K. et al. Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension. Arch Toxicol 83, 439–449 (2009). https://doi.org/10.1007/s00204-008-0363-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-008-0363-1